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Abstract
Bio-Strath is a plasmolyzed yeast product enriched with herbs, malt, honey and orange juice. In this study,
the effect of Equi-Strath, the adapted product for horses, on the equine immune system was evaluated. A rou-
tine influenza booster vaccination was used as a model to study the effects of Equi-Strath supplementation on
the immune response. Twenty healthy Franches-Montagnes stallions with pre-existing antibody levels were
randomly divided into a study group (SG, n = 10) receiving 0.06 mL/kg bodyweight of Equi-Strath, and a
control group (CG, n = 10), receiving the same amount of placebo, daily. The supplement and placebo were
given from week 1 until week 14 of the trial. After 10 weeks, the horses were vaccinated with a commercial
vaccine containing equine influenza strains of the H3N8 subtype. Antibody titres in blood were measured at
day 0 before vaccination, and 14 and 32 days after vaccination. In addition, a complete blood count (CBC) was
performed on day 0 and day 32. A linear increase of haemagglutination inhibition titres in both groups was
observed after vaccination, but with no difference between treatment groups. CBC components remained unaf-
fected by treatment. In conclusion, daily Equi-Strath supplementation did not affect the adaptive immune
response in stallions after a routine commercial H3N8 influenza booster vaccination.
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Introduction
Successful equine influenza vaccination in horses
stimulates an immune response, resulting in an
increase of the antigen-specific antibody production
(Van Maanen & Cullinane 2002). The extent of the
immune response, however, may be affected by sev-
eral factors. Folsom et al. (2001) observed how exer-
cise alters the immune response to equine influenza
virus and may increase susceptibility to infection in
ponies. In addition, Horohov et al. (1999) concluded
that older horses had a reduced immune function,
but were nevertheless more resistant to exercise-
induced immune suppression than younger horses.
Dietary effects on the immune response in horses
have also been reported. For instance, it was shown
by several groups that dietary consumption of
polyunsaturated fatty acids (PUFAs) can positively
affect the immune system in horses (Curtis et al.
2000; Adam et al. 2003). Furthermore, a greater anti-
gen-specific antibody response to equine influenza
was found in mature horses supplemented with a
fourfold increased amount of vitamin E (Baalsrud &
Overnes 1986). Knight & Tyznik (1990) observed a
higher antibody response in vitamin E supplemented
ponies challenged with packed sheep red blood cells
intramuscularly compared to ponies supplemented
with low levels of vitamin E. However, there are also
reports with dietary supplements that show unaf-
fected influenza vaccination responses (Brummer
et al. 2013) or decreasing immunoglobulin concentra-
tions in response to vaccination (Koke et al. 2015).
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Equi-Strath (Bio-Strath AG, Z€urich, Switzer-
land) for horses is, similar as Bio-Strath, a food sup-
plement comprised of plasmolyzed herbal yeast,
malt, honey and orange juice. Several studies have
shown positive effects of this supplement on the
immune system in vivo and in vitro. Leslie et al.
(1988, 1989) showed that daily administration of Bio-
Strath prolonged survival time in old mice, even
after infection with Staphylococcus aureus. As mor-
tality rates in mice infected with Staphylococcus aur-
eus were reduced and no changes in morbidity were
observed, it was suggested that Bio-Strath had a
stress protectant effect (Leslie et al. 1988). In a study
concerning the mode of action yielding higher sur-
vival rates, it could be determined that Bio-Strath
administration encourages more rapid and more effi-
cient mobilization of leucocytes including helper T-
lymphocytes as well as B-lymphocytes in mice (Joller
1988; Joller & Aeppli 1989). Similar findings were
seen in T-lymphocytes activation in vitro under the
stress of low-gravity as part of space biological inves-
tigations. The addition of the food supplement partly
restored or even increased expression of activation
markers on T-lymphocytes after low-gravity expo-
sure (Schwarzenberg et al. 2000). At present, no sci-
entific evidence is available illustrating the effects of
Equi-Strath on the horses’ health. The present
study examined the effect of Equi-Strath supple-
mentation on antibody production and haematologi-
cal parameters in response to a H3N8 influenza
booster vaccination in healthy Franches-Montagnes
stallions.
Material and methods
Animals
The experiment was carried out at the Swiss National
Stud in Avenches, and included 20 stallions of the
Franches-Montagnes breed. All horses used for the
study were clinically healthy at the start of the exper-
iment and had pre-existing antibody titres. The stal-
lions were on average 9.5  4.5 years old, and had a
bodyweight of 525  30 kg (mean  standard devia-
tion). All of them were primary vaccinated and had
received booster vaccinations every 6 months with
the same strain as used in the current study. The stal-
lions were kept in individual box stalls with straw or
wood chip bedding and were fed hay or haylage. In
addition, oats, barley, corn and pellets were fed daily.
Water and a mineral salt block were available ad libi-
tum. All animals were regularly exercised and were
turned out daily into a paddock throughout the
study.
Experimental design
The stallions were randomly divided into two groups
(drawn by lot), a study group (SG, n = 10;
8.6  4.9 years, mean  standard deviation) and a
control group (CG, n = 10; 10.5  4.1 years,
mean  standard deviation). The animals of the
study group each received daily a 0.06 mL/kg body-
weight of Equi-Strath, orally. The control group
(CG) received a placebo equivalent in consistency,
taste and colour as Equi-Strath, at the same quan-
tity daily. The feeding staff were blinded to the group
allocation of the stallions.
The experiment lasted for 14 weeks starting in
October 2013. The supplement and the placebo were
given from the beginning of the study (week 0) until
week 14 of the trial. This treatment was also used for
a parallel study on the effects of Equi-Strath sup-
plementation on semen quality and quantity (Burger
et al., manuscript in preparation).
Vaccination, blood sampling and immunological
assay
After 10 weeks of daily supplementation with Equi-
Strath, all horses were vaccinated against equine
influenza strains A/equine/South Africa/4/03 and A/
equine/Newmarket/2/93 of subtype H3N8 (Equilis
Prequenza ad. us. vet., MSD Animal Health GmbH,
Lucerne, Switzerland) as part of their half-yearly
routine booster vaccinations which were performed
with the same vaccine for the previous 18 months
The vaccine was administered by intramuscular
injection in the left side of the neck. Immediately
before week 10 of supplementation, which represents
day 0 of the present study, and twice after vaccina-
tion (days 14 and 32 after vaccination), blood was
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sampled and analysed in order to determine the
titres of specific antibodies. All blood samples were
collected from the left jugular vein, immediately cen-
trifuged (4000g for 10 min) and the serum frozen at
20°C until analysis. Antibody titres were deter-
mined via the haemagglutination inhibition (HI) test
using the European representative strain A/equine/
Suffolk/89 of subtype H3N8. The HI test was per-
formed on microtitre plates according to standard
procedures (Office International des Epizooties
(OIE), 1996). In addition, a complete blood count
was carried out (IDEXX Procyte Dx Haematology
Analyser, IDEXX Diavet AG, B€ach, Switzerland).
Statistical analysis
Titre data were log2 transformed, and subsequently
analysed using the mixed models procedure (SAS
Inst. Inc., Cary, NC) with repeated measures. Two
age classes were formed with horses < 9 years being
class 1, and horses ≥ 10 years being class 2. The
model included the group (horses with Equi-Strath
vs. horses with Placebo), the sampling time-point
(day 14 and day 32 after vaccination) and their inter-
action, and age class as fixed effects. In addition, the
titre before the vaccination (day 0) was used as
covariable in the model to adjust for initial differ-
ences between the two groups. The animal was speci-
fied as a random effect to accommodate repeated
measures of single individuals. The interaction effect
was dropped from the model as this was not shown
to be significant during initial analysis.
Data on changes in titre compared to the titre
measured before vaccination (Day 0) were analysed
with the general linear model (GLM) procedure
(SAS Inst. Inc., Cary, NC), including group and age
class as fixed effects in the model. The interaction
was dropped from the model as this was shown to be
not significant during initial analysis. Effects were
significant if P ≤ 0.05. Model assumptions were
checked using a graphical analysis of residuals and
normality of errors and random effects were assessed
based on qq-plots. The Mann–Whitney U test was
used to compare differences between the two groups
(SG vs. CG) for blood count components on day 0
before the vaccination, and for the change in blood
count components between day 0 and 32 after the
vaccination.
Results and discussion
Antibody titres
According to studies in mice infected with Staphy-
lococcus aureus (Joller 1988; Joller & Aeppli
1989), B-lymphocytes and T-lymphocytes are
expected to be more efficiently and more rapidly
activated after administration of Strath products.
To evaluate the effect of Equi-Strath on the
immune system of healthy stallions, antibody titres
were measured before and after H3N8 influenza
vaccination. The results of the present study
showed a numerically linear increase in haemag-
glutination inhibition titres in both groups after
vaccination. However, no statistically significant
effect (P = 0.66) of sampling time-point was
observed. In Gildea et al. (2011) as well as in
other publications, it was shown that the immune
response after vaccination peaks at 2 to 4 weeks.
With regard to the treatment, slightly higher titres
in response to vaccination were observed in
horses supplemented with Equi-Strath compared
to the horses receiving the placebo, although the
measured antibody titres of the stallions supple-
mented with Equi-Strath did not differ signifi-
cantly across time from those of the stallions
supplemented with the placebo (P = 0.65; Fig-
ure 1). Likely, our influenza vaccination was not a
sufficiently high and clinically relevant immune
challenge to observe any effects from Equi-
Strath on the immune system, as was observed
in the studies with mice infected with Staphylo-
coccus aureus (Joller 1988; Joller & Aeppli 1989).
The difference between day 14 to 0 and day 32 to
0 for means of titres (D HI; Figure 2) confirms a lin-
ear increase of the antibody titres over time, how-
ever, no significant effect of treatment was observed
for any of the calculated differences. The same
applies to the observed differences between day 14
to 32 being without a significant treatment effect.
Furthermore, we found an age class effect with
younger horses having more markedly increased HI
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titres compared to older horses (P = 0.02) during the
first 14 days after vaccination. Similarly Muirhead
et al. (2010), showed age was a factor affecting the
immune response, with aged horses having a signifi-
cantly reduced response to influenza vaccination
compared to the younger adult horses, likely because
they had higher pre-vaccination higher antibody
titres. In their review, Solana & Pawelec (1998) ques-
tion the use of booster vaccination in older horses as
this may lead to a state of unresponsiveness due to
‘clonal exhaustion’ of the antigen-specific lympho-
cytes. In the current study, Equi-Strath supplemen-
tation did not modulate the immune response in
stallions with respect to age.
Fig. 1. Haemagglutination inhibition titres (HI titres) of serum from stallions immunized with Equilis Prequenza ad. us. vet. vaccine over a
32-day period during supplementation with Equi-Strath or placebo. Results are means  standard error of the mean (SEM).
Fig. 2. Change in the haemagglutination inhibition titres (HI titres, log2) of serum from stallions immunized with Equilis Prequenza ad. us. vet.
vaccine over a 32-day period during supplementation with Equi-Strath or placebo.
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Complete blood count
The blood count did not show any significant differ-
ence between the study group and the control group
over time from day 0 until day 32. Interestingly, at the
day of vaccination, after 14 weeks of supplementation,
significant differences between the groups in the WBC
count, neutrophils, monocytes and eosinophils
(Table 1) were found. The total WBC count was
increased in the control group compared to the study
group (P = 0.01). Also neutrophils (P = 0.02), mono-
cytes (P = 0.03) and eosinophils (P = 0.01) were
increased in the placebo control group compared to
the study group. Even though, the observed differences
were statistically significant, these small effects are not
likely to be clinically relevant. As no blood samples for
blood count were taken before the beginning of the
administration of Equi-Strath no comparison before
and after the 14 week supplementation could be made.
Conclusion
Daily Equi-Strath supplementation did not affect
the adaptive immune response in stallions after a
routine H3N8 influenza vaccination. An effect of
clinical relevance of Equi-Strath on the immune
system in horses was not demonstrated through
the immunological stimulation by booster vaccina-
tion in horses with pre-existing immunity. It
remains to be elucidated, whether Equi-Strath
supplementation may induce a protective effect in
horses exposed to a stronger immune challenge or
in immunologically na€ıve horses without any
previous vaccination.
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Table 1. Blood count (mean  SEM) in stallions supplemented with Equi-Strath or placebo.
Parameter Days relative to vaccination Experimental group P-value Mann–Whitney
Equi-Strath Placebo
RBC (x1012/L) 0 7.29  0.108 7.36  0.115 0.48
Red blood cells Changed 0–32 0.10  0.16 0.06  0.07 0.58
PCV (%) 0 32.66  0.551 33.07  0.518 0.41
Packed cell volume Changed 0–32 0.08  0.76 0.14  0.34 0.74
HGB (g/dL) 0 11.93  0.156 12.06  0.153 0.40
Haemoglobin Changed 0–32 0.15  0.23 0.04  0.09 0.55
WBC (x 109/L) 0 5.47  0.277 6.56  0.225 0.01
White blood cells Changed 0–32 0.20  0.43 0.33  0.17 0.23
NEU (x109/L) 0 3.05  0.199 3.73  0.172 0.02
Neutrophils Changed 0–32 0.02  0.27 0.06  0.12 0.63
LYM (x109/L) 0 2.01  0.090 2.25  0.088 0.10
Lymphocytes Changed 0–32 0.19  0.15 0.26  0.08 0.35
MONO (x109/L) 0 0.27  0.019 0.32  0.015 0.03
Monocytes Changed 0–32 0.01  0.03 0.00  0.02 0.52
EOS (x109/L) 0 0.12  0.020 0.25  0.047 0.01
Eosinophils Changed 0–32 0.01  0.01 0.02  0.04 0.97
BASO (x109/L) 0 0.019  0.005 0.021  0.004 0.70
Basophils Changed 0–32 0.00  0.00 0.01  0.01 0.11
PTL (K/lL) 0 105.7  11.09 124.1  7.01 0.33
Platelet count Changed 0–32 3.70  9.89 0.40  11.20 0.85
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